{"product_id":"moffitt-cancer-center-20th-annual-clinical-breakthroughs-and-challenges-in-hematologic-malignancies-2025","title":"Moffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025","description":"\u003cdiv\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eMoffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 14 videos + 14 audios + 14 file sub vtt + 14 pdfs, size: 3.89 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: hematologists, oncologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eInformation:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003eThis annual conference is a premier forum designed to present the most recent diagnostic and therapeutic advances in hematologic malignancies. Hosted by the \u003cb data-index-in-node=\"157\" data-path-to-node=\"2\"\u003eMoffitt Cancer Center\u003c\/b\u003e, one of the nation’s leading cancer research institutes, the 2025 event continued its tradition of offering “breakthrough” updates that bridge the gap between research and bedside practice. The program is structured around interactive debates and “State of the Art” lectures, providing a comprehensive review of lymphoid and myeloid malignancies, plasma cell dyscrasias, and the evolving landscape of cellular immunotherapies.\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"3\"\u003e+ What You Will Learn\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"4\"\u003eAttendees were able to:\u003c\/p\u003e\n\u003cul data-path-to-node=\"5\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,0,0\"\u003eEvaluate\u003c\/b\u003e the latest clinical data regarding \u003cb data-index-in-node=\"44\" data-path-to-node=\"5,0,0\"\u003eCAR T-cell therapy\u003c\/b\u003e and \u003cb data-index-in-node=\"67\" data-path-to-node=\"5,0,0\"\u003ebispecific antibodies\u003c\/b\u003e, specifically their sequencing and toxicity management in lymphoma and myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,1,0\"\u003eDiscuss\u003c\/b\u003e the role of \u003cb data-index-in-node=\"20\" data-path-to-node=\"5,1,0\"\u003eMeasurable Residual Disease (MRD)\u003c\/b\u003e testing in guiding treatment decisions for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,2,0\"\u003eIdentify\u003c\/b\u003e new therapeutic targets and agents for \u003cb data-index-in-node=\"48\" data-path-to-node=\"5,2,0\"\u003eRelapsed\/Refractory\u003c\/b\u003e Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,3,0\"\u003eAnalyze\u003c\/b\u003e the “Hot Topics” in blood cancers, including the management of \u003cb data-index-in-node=\"71\" data-path-to-node=\"5,3,0\"\u003eclonal hematopoiesis\u003c\/b\u003e and its risk implications for older adults.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,4,0\"\u003eDebate\u003c\/b\u003e controversial management strategies, such as the use of hypomethylating agents prior to transplant in high-risk MDS, through interactive pro\/con sessions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"5,5,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"5,5,0\"\u003eImplement\u003c\/b\u003e best practices for managing complications of novel immunotherapies, including \u003cb data-index-in-node=\"88\" data-path-to-node=\"5,5,0\"\u003eCytokine Release Syndrome (CRS)\u003c\/b\u003e and neurotoxicity (ICANS).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"6\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"6\"\u003e+ Event Details\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"7\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,0,0\"\u003eDate:\u003c\/b\u003e January 25, 2025\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"7,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,1,0\"\u003eLocation:\u003c\/b\u003e Florida (Historically held at venues like \u003ci data-index-in-node=\"52\" data-path-to-node=\"7,1,0\"\u003eThe Don CeSar\u003c\/i\u003e in St. Pete Beach or \u003ci data-index-in-node=\"87\" data-path-to-node=\"7,1,0\"\u003eDisney’s Grand Floridian\u003c\/i\u003e in Orlando; the 21st Annual is confirmed for St. Pete Beach).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cb data-index-in-node=\"0\" data-path-to-node=\"7,3,0\"\u003eOrganizer:\u003c\/b\u003e Moffitt Cancer Center\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"8\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"8\"\u003e+ Who Should Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp data-path-to-node=\"9\"\u003eThe conference is tailored for the interdisciplinary hematology-oncology team:\u003c\/p\u003e\n\u003cul data-path-to-node=\"10\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,0,0\"\u003eHematologists\u003c\/b\u003e and Medical Oncologists\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,1,0\"\u003eOncology Nurses\u003c\/b\u003e and Nurse Practitioners\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,2,0\"\u003ePhysician Assistants\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,3,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,3,0\"\u003ePharmacists\u003c\/b\u003e specializing in oncology\/hematology\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"10,4,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"10,4,0\"\u003eResearch Scientists\u003c\/b\u003e and Fellows\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"11\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"11\"\u003e+ Why Attend\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"12\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,0,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,0,0\"\u003eCutting-Edge Science:\u003c\/b\u003e Moffitt Cancer Center is a leader in cellular therapy (CAR T), and this conference provides direct access to the faculty driving these innovations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,1,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,1,0\"\u003eDebate Format:\u003c\/b\u003e Unlike standard lecture series, this event features “Interactive Debates” (e.g., \u003ci data-index-in-node=\"96\" data-path-to-node=\"12,1,0\"\u003eTransplant vs. CAR T in Myeloma\u003c\/i\u003e), which help clinicians understand the nuance behind conflicting guidelines.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"12,2,0\"\u003e\u003cb data-index-in-node=\"0\" data-path-to-node=\"12,2,0\"\u003eASH Updates:\u003c\/b\u003e Held shortly after the American Society of Hematology (ASH) annual meeting, this course serves as a critical “post-ASH” review, distilling thousands of abstracts into actionable clinical pearls for the coming year.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eManagement of First MM Relapse Debate – Cilta-Cel for All – No\u003c\/li\u003e\n\u003cli\u003eManagement of First MM Relapse Debate – Cilta-Cel for All – Yes\u003c\/li\u003e\n\u003cli\u003eState-of-the-Art – Understanding Precursor States – CHIP and CCUS\u003c\/li\u003e\n\u003cli\u003e2025 Updates on Treating Anemia in LR-MDS\u003c\/li\u003e\n\u003cli\u003eDebate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS \u0026amp; AML – Yes\u003c\/li\u003e\n\u003cli\u003eDebate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS \u0026amp; AML – No\u003c\/li\u003e\n\u003cli\u003eBeyond CAR-T – Management of Post-BCMA CAR-T Relapse in RRMM\u003c\/li\u003e\n\u003cli\u003eHow I Treat High-Risk Multiple Myeloma – Interactive Case Discussion\u003c\/li\u003e\n\u003cli\u003eAQUILA Trial – Daratumumab vs. Active Monitoring in SMM – Perspectives for Practice\u003c\/li\u003e\n\u003cli\u003eSummary of Data for Transplant-Ineligible NDMM – Proposed SoC Approach\u003c\/li\u003e\n\u003cli\u003eLR-MDS Updates + Panel Discussion – Focus on Ph3 IMerge Trial\u003c\/li\u003e\n\u003cli\u003eRevmibeni for KMT2Ar RR Acute Leukemia – AUGMENT-101 Trial – Impact on Treatment Landscape\u003c\/li\u003e\n\u003cli\u003eClinical Application of Practice-Changing SWOG S1826 Trial – Nivo+AVD vs. BV+AVD in 1L Advanced Stage cHL\u003c\/li\u003e\n\u003cli\u003eGolcadomide + R-CHOP in High-Risk, Untreated Aggressive B-cell Lymphoma – Panel Discussion on Future of 1L Therapy in DLBCL\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954548248674,"sku":"MED-AMB05880","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/file_00000000f68072439c71e9dfa9644da8-1.png?v=1779379502","url":"https:\/\/meducourse.com\/products\/moffitt-cancer-center-20th-annual-clinical-breakthroughs-and-challenges-in-hematologic-malignancies-2025","provider":"Meducourse","version":"1.0","type":"link"}